Pfizer Inc. (PFE)
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
The company's problems are no longer deniable.
Pfizer's Activist Battle Might Fizzle---but Its Stock Probably Won't
The pharmaceutical company's stock is relatively cheap, representing an opportunity for patient value investors.
Final Trades: Pfizer, S&P Aerospace and Defense, and Live Nation
Today's Final Trades from the Investment Committee.
Gear Up for Pfizer (PFE) Q3 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Pfizer Q3 Preview: Why The Stock Is A Buy Ahead Of Earnings
Pfizer's Q3 consensus estimate is likely to be exceeded as the successful integration of Seagen assets and the deleveraging efforts should lead to stronger EPS growth in the coming quarters. In Q2, we saw that management's approach is effective as they have successfully reduced operating costs relative to sales, resulting in higher margins. PFE has raised adjusted EPS guidance for 2024, now expecting adjusted EPS of $2.45-2.65, up from $2.15-2.35, moving the middle of the range up $0.30.
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Activist investor Starboard Value has sharpened its criticism of Pfizer Inc. PFE, holding the pharmaceutical giant's management accountable for failing to deliver on its promises of innovation and growth.
